{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,6]],"date-time":"2026-09-06T00:56:04Z","timestamp":1788656164814,"version":"build-2803163510"},"reference-count":40,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,5,31]],"date-time":"2025-05-31T00:00:00Z","timestamp":1748649600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100006190","name":"Research and Development","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006190","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100013170","name":"Ono Pharmaceutical Co Ltd","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100013170","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","ejcancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Cancer"],"published-print":{"date-parts":[[2025,6]]},"DOI":"10.1016\/j.ejca.2025.115537","type":"journal-article","created":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T10:47:38Z","timestamp":1748774858000},"page":"115537","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"special_numbering":"C","title":["Phase II trial dedicated to non-selected, pretreated cutaneous angiosarcoma: Efficacy of nivolumab (AngioCheck Study)"],"prefix":"10.1016","volume":"224","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3010-8496","authenticated-orcid":false,"given":"Yasuhiro","family":"Fujisawa","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2763-7346","authenticated-orcid":false,"given":"Kenjiro","family":"Namikawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shoichiro","family":"Ishitsuki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koji","family":"Yoshino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9360-5994","authenticated-orcid":false,"given":"Taiki","family":"Isei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroshi","family":"Kato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2196-7600","authenticated-orcid":false,"given":"Teruki","family":"Yanagi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuki","family":"Yamamoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroshi","family":"Uchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2907-640X","authenticated-orcid":false,"given":"Masahito","family":"Yasuda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3093-0386","authenticated-orcid":false,"given":"Kazushi","family":"Maruo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3233-1045","authenticated-orcid":false,"given":"Eiji","family":"Sugihara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7365-947X","authenticated-orcid":false,"given":"Atsushi","family":"Otsuka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejca.2025.115537_bib1","doi-asserted-by":"crossref","first-page":"1914","DOI":"10.1002\/1097-0142(20010515)91:10<1914::AID-CNCR1214>3.0.CO;2-3","article-title":"Predictive value of grade for metastasis development in the main histologic types of adult soft tissue sarcomas: a study of 1240 patients from the French Federation of Cancer Centers Sarcoma Group","volume":"91","author":"Coindre","year":"2001","journal-title":"Cancer"},{"key":"10.1016\/j.ejca.2025.115537_bib2","unstructured":"Network. NCI. Soft tissue sarcoma incidence and survival; tumours diagnosed in England between 1985 and 2009; 2012. \u3008www.ncin.org.uk\u3009."},{"key":"10.1016\/j.ejca.2025.115537_bib3","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.1097\/SLA.0b013e3181dbb75a","article-title":"Angiosarcoma: clinical and molecular insights","volume":"251","author":"Lahat","year":"2010","journal-title":"Ann Surg"},{"key":"10.1016\/j.ejca.2025.115537_bib4","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1002\/cncr.23571","article-title":"Cutaneous soft tissue sarcoma incidence patterns in the U.S.: an analysis of 12,114 cases","volume":"113","author":"Rouhani","year":"2008","journal-title":"Cancer"},{"key":"10.1016\/j.ejca.2025.115537_bib5","doi-asserted-by":"crossref","DOI":"10.1111\/cas.15823","article-title":"Epidemiology of skin cancer based on Japan's National Cancer Registry 2016-2017","author":"Ogata","year":"2023","journal-title":"Cancer Sci"},{"key":"10.1016\/j.ejca.2025.115537_bib6","doi-asserted-by":"crossref","first-page":"5269","DOI":"10.1200\/JCO.2008.17.3146","article-title":"Phase II trial of weekly paclitaxel for unresectable angiosarcoma: the ANGIOTAX Study","volume":"26","author":"Penel","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2025.115537_bib7","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1002\/cncr.22822","article-title":"Docetaxel: a therapeutic option in the treatment of cutaneous angiosarcoma: report of 9 patients","volume":"110","author":"Nagano","year":"2007","journal-title":"Cancer"},{"key":"10.1016\/j.ejca.2025.115537_bib8","doi-asserted-by":"crossref","first-page":"3330","DOI":"10.1002\/cncr.26599","article-title":"Comparison of doxorubicin and weekly paclitaxel efficacy in metastatic angiosarcomas","volume":"118","author":"Italiano","year":"2012","journal-title":"Cancer"},{"key":"10.1016\/j.ejca.2025.115537_bib9","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1111\/bjd.19042","article-title":"The efficacy of eribulin mesylate for patients with cutaneous angiosarcoma previously treated with taxane: a multicentre prospective observational study","volume":"183","author":"Fujisawa","year":"2020","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.ejca.2025.115537_bib10","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1634\/theoncologist.2011-0237","article-title":"Sorafenib for patients with advanced angiosarcoma: a phase II Trial from the French Sarcoma Group (GSF\/GETO)","volume":"17","author":"Ray-Coquard","year":"2012","journal-title":"oncologist"},{"key":"10.1016\/j.ejca.2025.115537_bib11","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1080\/0284186X.2016.1234068","article-title":"Pazopanib in advanced vascular sarcomas: an EORTC Soft Tissue and Bone Sarcoma Group (STBSG) retrospective analysis","volume":"56","author":"Kollar","year":"2017","journal-title":"Acta Oncol"},{"key":"10.1016\/j.ejca.2025.115537_bib12","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1001\/jamaoncol.2021.3547","article-title":"Efficacy and Safety of TRC105 plus pazopanib vs pazopanib alone for treatment of patients with advanced angiosarcoma: a randomized clinical trial","volume":"8","author":"Jones","year":"2022","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.ejca.2025.115537_bib13","doi-asserted-by":"crossref","first-page":"2797","DOI":"10.1200\/JCO.2015.60.8505","article-title":"Paclitaxel given once per week with or without bevacizumab in patients with advanced angiosarcoma: a randomized phase II trial","volume":"33","author":"Ray-Coquard","year":"2015","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2025.115537_bib14","doi-asserted-by":"crossref","first-page":"2500","DOI":"10.1056\/NEJMc1713444","article-title":"Tumor mutational burden and response rate to PD-1 inhibition","volume":"377","author":"Yarchoan","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejca.2025.115537_bib15","doi-asserted-by":"crossref","DOI":"10.1002\/cncr.31517","article-title":"Rationale and emerging strategies for immune checkpoint blockade in soft tissue sarcoma","author":"Wisdom","year":"2018","journal-title":"Cancer"},{"key":"10.1016\/j.ejca.2025.115537_bib16","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.1158\/2326-6066.CIR-18-0121","article-title":"Successful Treatment of HIV-associated kaposi sarcoma with immune checkpoint blockade","volume":"6","author":"Galanina","year":"2018","journal-title":"Cancer Immunol Res"},{"key":"10.1016\/j.ejca.2025.115537_bib17","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1093\/annonc\/mdy006","article-title":"PD-1 blockade with nivolumab in endemic Kaposi sarcoma","volume":"29","author":"Delyon","year":"2018","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ejca.2025.115537_bib18","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1038\/s41591-019-0749-z","article-title":"The Angiosarcoma Project: enabling genomic and clinical discoveries in a rare cancer through patient-partnered research","volume":"26","author":"Painter","year":"2020","journal-title":"Nat Med"},{"key":"10.1016\/j.ejca.2025.115537_bib19","doi-asserted-by":"crossref","first-page":"3383","DOI":"10.1002\/cncr.34370","article-title":"Clinical activity of checkpoint inhibitors in angiosarcoma: A retrospective cohort study","volume":"128","author":"Ravi","year":"2022","journal-title":"Cancer"},{"key":"10.1016\/j.ejca.2025.115537_bib20","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1186\/s40425-019-0689-7","article-title":"Angiosarcoma patients treated with immune checkpoint inhibitors: a case series of seven patients from a single institution","volume":"7","author":"Florou","year":"2019","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.ejca.2025.115537_bib21","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2021-002990","article-title":"Multicenter phase II trial (SWOG S1609, cohort 51) of ipilimumab and nivolumab in metastatic or unresectable angiosarcoma: a substudy of dual anti-CTLA-4 and anti-PD-1 blockade in rare tumors (DART)","volume":"9","author":"Wagner","year":"2021","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.ejca.2025.115537_bib22","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1126\/science.aaa1348","article-title":"Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer","volume":"348","author":"Rizvi","year":"2015","journal-title":"Science"},{"key":"10.1016\/j.ejca.2025.115537_bib23","first-page":"1100","article-title":"[Bilateral Pneumothorax due to Pulmonary Metastasis from Angiosarcoma of the Forehead\uff1bReport of a Case]","volume":"68","author":"Nakata","year":"2015","journal-title":"Kyobu Geka"},{"key":"10.1016\/j.ejca.2025.115537_bib24","doi-asserted-by":"crossref","first-page":"11503","DOI":"10.1200\/JCO.2023.41.16_suppl.11503","article-title":"A multicenter phase II study of cabozantinib +\u2009nivolumab for patients (pts) with advanced angiosarcoma (AS) previously treated with a taxane (Alliance A091902)","volume":"41","author":"Grilley-Olson","year":"2023","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2025.115537_bib25","doi-asserted-by":"crossref","first-page":"1945","DOI":"10.1158\/1078-0432.CCR-23-3206","article-title":"Radiotherapy Enhances Metastasis Through Immune Suppression by Inducing PD-L1 and MDSC in Distal Sites","volume":"30","author":"Hou","year":"2024","journal-title":"Clin Cancer Res: J Am Assoc Cancer Res"},{"key":"10.1016\/j.ejca.2025.115537_bib26","doi-asserted-by":"crossref","DOI":"10.4161\/onci.28518","article-title":"Radiation fosters dose-dependent and chemotherapy-induced immunogenic cell death","volume":"3","author":"Golden","year":"2014","journal-title":"Oncoimmunology"},{"key":"10.1016\/j.ejca.2025.115537_bib27","doi-asserted-by":"crossref","first-page":"153","DOI":"10.3389\/fonc.2012.00153","article-title":"Radiation as an immunological adjuvant: current evidence on dose and fractionation","volume":"2","author":"Demaria","year":"2012","journal-title":"Front Oncol"},{"key":"10.1016\/j.ejca.2025.115537_bib28","doi-asserted-by":"crossref","first-page":"1976","DOI":"10.1056\/NEJMoa1716078","article-title":"Neoadjuvant PD-1 blockade in resectable lung cancer","volume":"378","author":"Forde","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejca.2025.115537_bib29","doi-asserted-by":"crossref","first-page":"1350","DOI":"10.1126\/science.aar4060","article-title":"Cancer immunotherapy using checkpoint blockade","volume":"359","author":"Ribas","year":"2018","journal-title":"Science"},{"key":"10.1016\/j.ejca.2025.115537_bib30","doi-asserted-by":"crossref","first-page":"2994","DOI":"10.1002\/1878-0261.12851","article-title":"Targeting immunogenic cell death in cancer","volume":"14","author":"Ahmed","year":"2020","journal-title":"Mol Oncol"},{"key":"10.1016\/j.ejca.2025.115537_bib31","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1038\/s41416-018-0333-1","article-title":"Immunosuppression mediated by myeloid-derived suppressor cells (MDSCs) during tumour progression","volume":"120","author":"Groth","year":"2019","journal-title":"Br J Cancer"},{"key":"10.1016\/j.ejca.2025.115537_bib32","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/j.immuni.2013.06.014","article-title":"Mechanism of action of conventional and targeted anticancer therapies: reinstating immunosurveillance","volume":"39","author":"Zitvogel","year":"2013","journal-title":"Immunity"},{"key":"10.1016\/j.ejca.2025.115537_bib33","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1038\/nrclinonc.2018.29","article-title":"Enhancing cancer immunotherapy using antiangiogenics: opportunities and challenges","volume":"15","author":"Fukumura","year":"2018","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1016\/j.ejca.2025.115537_bib34","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2021-003091","article-title":"Tumor mutational burden predicts the efficacy of pembrolizumab monotherapy: a pan-tumor retrospective analysis of participants with advanced solid tumors","volume":"10","author":"Cristescu","year":"2022","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.ejca.2025.115537_bib35","doi-asserted-by":"crossref","first-page":"2598","DOI":"10.1158\/1535-7163.MCT-17-0386","article-title":"Tumor mutational burden as an independent predictor of response to immunotherapy in diverse cancers","volume":"16","author":"Goodman","year":"2017","journal-title":"Mol Cancer Ther"},{"key":"10.1016\/j.ejca.2025.115537_bib36","doi-asserted-by":"crossref","first-page":"4816","DOI":"10.3390\/cancers13194816","article-title":"Genomic landscape of angiosarcoma: a targeted and immunotherapy biomarker analysis","volume":"13","author":"Espejo-Freire","year":"2021","journal-title":"Cancers"},{"key":"10.1016\/j.ejca.2025.115537_bib37","doi-asserted-by":"crossref","first-page":"5833","DOI":"10.1172\/JCI139080","article-title":"Multiomic analysis and immunoprofiling reveal distinct subtypes of human angiosarcoma","volume":"130","author":"Chan","year":"2020","journal-title":"J Clin Investig"},{"key":"10.1016\/j.ejca.2025.115537_bib38","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2021-004149","article-title":"Clinical, genomic, and transcriptomic correlates of response to immune checkpoint blockade-based therapy in a cohort of patients with angiosarcoma treated at a single center","volume":"10","author":"Rosenbaum","year":"2022","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.ejca.2025.115537_bib39","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1200\/JGO.2016.005843","article-title":"Positive PD-L1 expression predicts worse outcome in cutaneous angiosarcoma","volume":"3","author":"Shimizu","year":"2017","journal-title":"J Glob Oncol"},{"key":"10.1016\/j.ejca.2025.115537_bib40","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2016.1253657","article-title":"Infiltration of PD-1-positive cells in combination with tumor site PD-L1 expression is a positive prognostic factor in cutaneous angiosarcoma","volume":"6","author":"Honda","year":"2017","journal-title":"Oncoimmunology"}],"container-title":["European Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804925003193?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804925003193?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,6,12]],"date-time":"2025-06-12T04:07:48Z","timestamp":1749701268000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0959804925003193"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6]]},"references-count":40,"alternative-id":["S0959804925003193"],"URL":"https:\/\/doi.org\/10.1016\/j.ejca.2025.115537","relation":{},"ISSN":["0959-8049"],"issn-type":[{"value":"0959-8049","type":"print"}],"subject":[],"published":{"date-parts":[[2025,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Phase II trial dedicated to non-selected, pretreated cutaneous angiosarcoma: Efficacy of nivolumab (AngioCheck Study)","name":"articletitle","label":"Article Title"},{"value":"European Journal of Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejca.2025.115537","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Author(s). Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"115537"}}